Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

The Guardian - UK

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly just posted its fastest revenue growth ever, putting shares up 40% in less than three months. The stock continues to have strong long-term potential.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose

The Independent UK

Trump close to deal to allow Medicare coverage of weight loss drugs

A deal could significantly expand seniors' access to the popular drugs.

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

What's Up With The Rise In Eli Lilly Stock Today?

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Independent UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

The Guardian - UK

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Get all your
news in one place.

100’s of premium titles.
One news app.

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

International Business Times UK

What Is Retatrutide? Viral Weight Loss Drug Claimed to Battle Obesity—But Is It Even Real?

Influencers are promoting the weight-loss drug Retatrutide online, but it's an unapproved medication. Learn about the dangers of fake versions and when the real drug might actually be available.

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly and Company (NYSE:LLY) shares are trading lower Friday, among other GLP-1 drug manufacturers, following President Donald Trump‘s comments that fat-loss drugs will be a lot lower in price.

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price.

The Independent UK

Warning after ‘King Kong’ of weight-loss jabs found being sold illegally on social media

Former Big Brother housemate says she thought she was ‘going to die’ after buying weight-loss jab from TikTok

Here's What to Expect From Eli Lilly’s Next Earnings Report

What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?

People

148,883 stories

Aisleyne HorganWallace

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the White House

the Federal Reserve

the Wall Street Journal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

315,456 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play